News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>UBS Lifts Intel (INTC.US) TP to USD65; 14A PDK Becomes Key Catalyst
UBS published a research report on Intel (INTC.US), which saw resilient PC demand, with server CPU demand also swelling. The company raised prices by about 10%, and further price i...
Reset
Send
The window will close in 5 seconds
<Research>UBS Lifts Intel (INTC.US) TP to USD65; 14A PDK Becomes Key Catalyst
Close
Recommend
8
Positive
6
Negative
6
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Gold ETF share!

UBS published a research report on Intel (INTC.US)      , which saw resilient PC demand, with server CPU demand also swelling. The company raised prices by about 10%, and further price increases were expected within the year, particularly in the enterprise server.

The broker slightly raised its 1Q revenue forecast for the group from the previous USD12.2 billion to USD12.5 billion, while maintaining its EPS forecast at USD0.06. For 2026-28, revenue forecasts were lifted from USD51.1 billion, USD52.4 billion and USD56.1 billion to USD53.1 billion, USD55.1 billion and USD58.5 billion, respectively. EPS forecasts were also revised up from USD0.35, USD0.6 and USD0.92 to USD0.44, USD0.75 and USD1.05, respectively.

UBS noted that Intel's foundry business outlook is improving, particularly in relation to its 14A process technology. It expected customers including Google, Apple (AAPL.US)      , AMD (AMD.US)      and NVIDIA (NVDA.US)      to sign foundry commitments this fall. In addition, the potential scenario of merging the Ohio wafer fab project with Elon Musk's TeraFab adds confidence to the long-term prospects of the foundry business.

UBS maintained a Neutral rating on Intel, raising its TP from USD51 to USD65.
(Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.